Philip Hedge (PhD) is a bioscientist with 24 years of experience of cancer drug discovery at AstraZeneca. Philip has conducted and led research across all phases of research, including new target discovery, lead generation, lead optimisation and preclinical support for compounds in clinical development. In his 10 years as Director of Cancer Bioscience he led a large group of bioscientists in delivering the preclinical and translational science in support of the AZ Oncology portfolio. As a project leader he has led many cross functional drug discovery projects and collaborations. His strategic vision and drive has brought many new technological and scientific innovations into the organisation. He offers clear insight into the critical studies required to effectively evaluate target relevance in disease, identify clinical candidates and position experimental therapeutics appropriately in the clinic.